Positive interim safety, tolerability, and specificity results from an initial dosing group of patients allowed the trial to advance to its medium dosing regimen, the company reported in a press release.
ACI-35.030, being developed in collaboration with Janssen Pharmaceuticals, mimics the structure of the toxic version of the tau protein — phosphorylated tau — that underlies key features of Alzheimer's pathology, such as disrupted communication between nerve cells.
By triggering an immune reaction to phosphorylated tau, the antibodies generated by ACI-35.030 have the potential to limit the occurrence and spread of tau pathology throughout the brain.
“The fact that ACI-35.030 shows encouraging safety and immunogenicity at the lowest dose in this elderly patient population is highly meaningful and we look forward to quickly enrolling this next dosing group," Anrea Pfeifer, AC Immune's CEO, said in the release.
"Tau-targeted approaches may have a